Fresenius Kabi AG
Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Within I.V. generic drugs, Fresenius Kabi counts among the leading suppliers in the U.S. market.
The company is focused on the therapy and care of critically and chronically ill patients in and outside the hospital.
Fresenius Kabi has more than 22,500 employees worldwide and a global network of around 55 sales organizations and more than 60 production sites. In 2010, Fresenius Kabi's sales were € 3,672 million and the company's EBIT was € 737 million.
Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE & Co. KGaA.
Key Figures
| €m | 2010 | 2009 | Change |
| Sales |
3,672 |
3,086 |
19% |
| EBITDA |
893 |
742 |
20% |
| EBIT |
737 |
607 |
21% |
| Net Income* |
294 |
200 |
47% |
| Employees |
22,851 |
21,872 |
4% |
*Net income attributable to Fresenius Kabi AG.